361 related articles for article (PubMed ID: 25681658)
21. Effects of ras and von Hippel-Lindau (VHL) gene mutations on hypoxia-inducible factor (HIF)-1alpha, HIF-2alpha, and vascular endothelial growth factor expression and their regulation by the phosphatidylinositol 3'-kinase/Akt signaling pathway.
Blancher C; Moore JW; Robertson N; Harris AL
Cancer Res; 2001 Oct; 61(19):7349-55. PubMed ID: 11585776
[TBL] [Abstract][Full Text] [Related]
22. Identification of novel hypoxia dependent and independent target genes of the von Hippel-Lindau (VHL) tumour suppressor by mRNA differential expression profiling.
Wykoff CC; Pugh CW; Maxwell PH; Harris AL; Ratcliffe PJ
Oncogene; 2000 Dec; 19(54):6297-305. PubMed ID: 11175344
[TBL] [Abstract][Full Text] [Related]
23. Transgenic models to understand hypoxia-inducible factor function.
Doedens A; Johnson RS
Methods Enzymol; 2007; 435():87-105. PubMed ID: 17998050
[TBL] [Abstract][Full Text] [Related]
24. Role of hypoxia-inducible factor (HIF)-1alpha versus HIF-2alpha in the regulation of HIF target genes in response to hypoxia, insulin-like growth factor-I, or loss of von Hippel-Lindau function: implications for targeting the HIF pathway.
Carroll VA; Ashcroft M
Cancer Res; 2006 Jun; 66(12):6264-70. PubMed ID: 16778202
[TBL] [Abstract][Full Text] [Related]
25. [Cellular and tissue hypoxia--role of the von Hippel Lindau gene and hypoxia-inducible factor-1].
Sýkora V; Necas E
Cas Lek Cesk; 2003; 142(10):595-8. PubMed ID: 14635422
[TBL] [Abstract][Full Text] [Related]
26. VHL and HIF signalling in renal cell carcinogenesis.
Baldewijns MM; van Vlodrop IJ; Vermeulen PB; Soetekouw PM; van Engeland M; de Bruïne AP
J Pathol; 2010 Jun; 221(2):125-38. PubMed ID: 20225241
[TBL] [Abstract][Full Text] [Related]
27. The bone microenvironment in metastasis; what is special about bone?
Bussard KM; Gay CV; Mastro AM
Cancer Metastasis Rev; 2008 Mar; 27(1):41-55. PubMed ID: 18071636
[TBL] [Abstract][Full Text] [Related]
28. Endolymphatic sac tumors in patients with and without von Hippel-Lindau disease: the role of genetic mutation, von Hippel-Lindau protein, and hypoxia inducible factor-1alpha expression.
Jensen RL; Gillespie D; House P; Layfield L; Shelton C
J Neurosurg; 2004 Mar; 100(3):488-97. PubMed ID: 15035285
[TBL] [Abstract][Full Text] [Related]
29. Hypoxia and hypoxia-inducible factor-1 expression enhance osteolytic bone metastases of breast cancer.
Hiraga T; Kizaka-Kondoh S; Hirota K; Hiraoka M; Yoneda T
Cancer Res; 2007 May; 67(9):4157-63. PubMed ID: 17483326
[TBL] [Abstract][Full Text] [Related]
30. New therapeutic targets for cancer bone metastasis.
Krzeszinski JY; Wan Y
Trends Pharmacol Sci; 2015 Jun; 36(6):360-73. PubMed ID: 25962679
[TBL] [Abstract][Full Text] [Related]
31. Hypoxia-regulated expression of attenuated diphtheria toxin A fused with hypoxia-inducible factor-1alpha oxygen-dependent degradation domain preferentially induces apoptosis of hypoxic cells in solid tumor.
Koshikawa N; Takenaga K
Cancer Res; 2005 Dec; 65(24):11622-30. PubMed ID: 16357173
[TBL] [Abstract][Full Text] [Related]
32. Cell and Signal Components of the Microenvironment of Bone Metastasis Are Affected by Hypoxia.
Bendinelli P; Maroni P; Matteucci E; Desiderio MA
Int J Mol Sci; 2016 May; 17(5):. PubMed ID: 27187355
[TBL] [Abstract][Full Text] [Related]
33. Expression of hypoxia-inducible factor 1alpha, hypoxia-inducible factor 2alpha, and von Hippel-Lindau protein in epithelial ovarian neoplasms and allelic loss of von Hippel-Lindau gene: nuclear expression of hypoxia-inducible factor 1alpha is an independent prognostic factor in ovarian carcinoma.
Osada R; Horiuchi A; Kikuchi N; Yoshida J; Hayashi A; Ota M; Katsuyama Y; Melillo G; Konishi I
Hum Pathol; 2007 Sep; 38(9):1310-20. PubMed ID: 17555795
[TBL] [Abstract][Full Text] [Related]
34. Targeting the Hepatocyte Growth Factor and c-Met Signaling Axis in Bone Metastases.
Whang YM; Jung SP; Kim MK; Chang IH; Park SI
Int J Mol Sci; 2019 Jan; 20(2):. PubMed ID: 30658428
[TBL] [Abstract][Full Text] [Related]
35. Regulation of cancer cell metabolism by hypoxia-inducible factor 1.
Semenza GL
Semin Cancer Biol; 2009 Feb; 19(1):12-6. PubMed ID: 19114105
[TBL] [Abstract][Full Text] [Related]
36. Identification of cyclin D1 and other novel targets for the von Hippel-Lindau tumor suppressor gene by expression array analysis and investigation of cyclin D1 genotype as a modifier in von Hippel-Lindau disease.
Zatyka M; da Silva NF; Clifford SC; Morris MR; Wiesener MS; Eckardt KU; Houlston RS; Richards FM; Latif F; Maher ER
Cancer Res; 2002 Jul; 62(13):3803-11. PubMed ID: 12097293
[TBL] [Abstract][Full Text] [Related]
37. Loss of von Hippel-Lindau protein causes cell density dependent deregulation of CyclinD1 expression through hypoxia-inducible factor.
Baba M; Hirai S; Yamada-Okabe H; Hamada K; Tabuchi H; Kobayashi K; Kondo K; Yoshida M; Yamashita A; Kishida T; Nakaigawa N; Nagashima Y; Kubota Y; Yao M; Ohno S
Oncogene; 2003 May; 22(18):2728-38. PubMed ID: 12743597
[TBL] [Abstract][Full Text] [Related]
38. Hypoxia-inducible factor 1 (HIF-1) pathway.
Semenza GL
Sci STKE; 2007 Oct; 2007(407):cm8. PubMed ID: 17925579
[TBL] [Abstract][Full Text] [Related]
39. Regulation of HIF prolyl hydroxylases by hypoxia-inducible factors.
Aprelikova O; Chandramouli GV; Wood M; Vasselli JR; Riss J; Maranchie JK; Linehan WM; Barrett JC
J Cell Biochem; 2004 Jun; 92(3):491-501. PubMed ID: 15156561
[TBL] [Abstract][Full Text] [Related]
40. von Hippel-Lindau protein adjusts oxygen sensing of the FIH asparaginyl hydroxylase.
Li SH; Chun YS; Lim JH; Huang LE; Park JW
Int J Biochem Cell Biol; 2011 May; 43(5):795-804. PubMed ID: 21316481
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
